These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9324622)

  • 1. [Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].
    Schnabel A; Csernok E; Schultz H; Stoffel M; Herzberg C; Carroll SF; Gross WL
    Med Klin (Munich); 1997 Jul; 92(7):389-93. PubMed ID: 9324622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.
    Walmsley RS; Zhao MH; Hamilton MI; Brownlee A; Chapman P; Pounder RE; Wakefield AJ; Lockwood CM
    Gut; 1997 Jan; 40(1):105-9. PubMed ID: 9155585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ANCA against bactericidal/permeability-increasing protein, azurocidin, calprotectin and defensins in rheumatic and infectious diseases: prevalence and clinical associations.
    Schultz H; Csernok E; Herlyn K; Reichel PH; Moosig F; Cornely OA; Fagerhol MK; Gross WL
    Clin Exp Rheumatol; 2003; 21(6 Suppl 32):S117-20. PubMed ID: 14740437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK).
    Lindgren S; Nilsson S; Nässberger L; Verbaan H; Wieslander J
    J Gastroenterol Hepatol; 2000 Apr; 15(4):437-42. PubMed ID: 10824890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders.
    Stoffel MP; Csernok E; Herzberg C; Johnson T; Carroll SF; Gross WL
    Clin Exp Immunol; 1996 Apr; 104(1):54-9. PubMed ID: 8603534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis.
    Xin G; Zhao MH; Wang HY
    Clin Diagn Lab Immunol; 2004 May; 11(3):559-62. PubMed ID: 15138182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein.
    Schinke S; Fellermann K; Herlyn K; Reichel PH; Fundke R; Stange EF; Gross WL; Schultz H
    Inflamm Bowel Dis; 2004 Nov; 10(6):763-70. PubMed ID: 15626895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin.
    Cooper T; Savige J; Nassis L; Paspaliaris B; Neeson P; Neil J; Knight KR; Daskalakis M; Doery JC
    Rheumatol Int; 2000; 19(4):129-36. PubMed ID: 10836522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis after immunisation with bacterial proteins.
    Savige J; Nassis L; Cooper T; Paspaliaris B; Martinello P; MacGregor D
    Clin Exp Rheumatol; 2002; 20(6):783-9. PubMed ID: 12508769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives.
    Radice A; Vecchi M; Bianchi MB; Sinico RA
    Clin Exp Rheumatol; 2000; 18(6):707-12. PubMed ID: 11138332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease.
    Yang JJ; Tuttle R; Falk RJ; Jennette JC
    Clin Exp Immunol; 1996 Jul; 105(1):125-31. PubMed ID: 8697620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases.
    Claise C; Johanet C; Bouhnik Y; Kapel N; Homberg JC; Poupon R
    Liver; 1996 Feb; 16(1):28-34. PubMed ID: 8868075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.
    Zhao MH; Jones SJ; Lockwood CM
    Clin Exp Immunol; 1995 Jan; 99(1):49-56. PubMed ID: 7813109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of bactericidal/permeability-increasing protein by perinuclear anti-neutrophil cytoplasmic antibody-positive sera from ulcerative colitis patients: prevalence and clinical significance.
    Vecchi M; Sinico A; Bianchi MB; Radice A; Gionchetti P; Campieri M; de Franchis R
    Scand J Gastroenterol; 1998 Dec; 33(12):1284-8. PubMed ID: 9930392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis.
    Sedivá A; Bartůnková J; Kolárová I; Hrusák O; Vávrová V; Macek M; Lockwood CM; Dunn AC
    J Autoimmun; 1998 Apr; 11(2):185-90. PubMed ID: 9650098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-neutrophil cytoplasmic antibodies in chronic inflammatory bowel disease. Prevalence and diagnostic role.
    Hertervig E; Wieslander J; Johansson C; Wiik A; Nilsson A
    Scand J Gastroenterol; 1995 Jul; 30(7):693-8. PubMed ID: 7481534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects.
    Audrain MA; Sesboüé R; Baranger TA; Elliott J; Testa A; Martin JP; Lockwood CM; Esnault VL
    Nephrol Dial Transplant; 2001 Jan; 16(1):39-44. PubMed ID: 11208991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineutrophil cytoplasm autoantibodies in patients with tuberculosis are directed against bactericidal/permeability increasing protein and are detected after treatment initiation.
    Esquivel-Valerio JA; Flores-Suárez LF; Rodríguez-Amado J; Garza-Elizondo MA; Rendón A; Salinas-Carmona MC
    Clin Exp Rheumatol; 2010; 28(1 Suppl 57):35-9. PubMed ID: 20412700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA.
    Schultz H; Csernok E; Johnston TW; Lockwood CM; Gross WL
    J Immunol Methods; 1997 Jul; 205(2):127-33. PubMed ID: 9294593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antineutrophil cytoplasmic antibodies in children with inflammatory bowel disease: prevalence and diagnostic value.
    Olives JP; Breton A; Hugot JP; Oksman F; Johannet C; Ghisolfi J; Navarro J; Cézard JP
    J Pediatr Gastroenterol Nutr; 1997 Aug; 25(2):142-8. PubMed ID: 9252899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.